Enter multiple symbols separated by commas



  • Sarissa Capital's biotech bets   Monday, 4 May 2015 | 11:25 AM ET
    Sarissa Capital's biotech bets

    Alex Denner, Sarissa Capital Management founder, discusses the opportunity in ARIAD Pharmaceuticals.

  • U.S. top court rejects hepatitis B drug patent case Monday, 4 May 2015 | 9:40 AM ET

    WASHINGTON, May 4- The U.S. Supreme Court on Monday brought to an end Bristol-Myers Squibb Co's attempt to revive patent protection for its Baraclude treatment for hepatitis B. The high court declined to hear Bristol-Myers' challenge to an appeals court ruling in favor of generic rival Teva Pharmaceutical Industries Ltd, which had successfully challenged the...

  • Unicorn plans to push diabetes drugs   Friday, 1 May 2015 | 11:17 AM ET
    Unicorn plans to push diabetes drugs

    Intarcia Therapeutics Inc. said it raised $225 million in the latest in a series of financing to support the development of its implantable drug-delivery pump for patients with diabetes.Kurt Graves, Intarcia Therapeutics chairman and CEO, discusses.

  • Growing market for Hep C drug   Friday, 1 May 2015 | 10:40 AM ET
    Growing market for Hep C drug

    A deadly disease is driving sales at pharmaceuticals. CNBC's Morgan Brennan reports.

  • *Cash return was planned after Novartis asset swap deal. Instead, Britain's biggest drugmaker could use cash flowing in from its far-reaching asset swap deal with Novartis to support its dividend, according to analysts at Goldman Sachs and Berenberg Bank. GSK said last year it intended to return 4 billion pounds to shareholders in 2015 through a so-called B...

  • Gilead 1Q profit doubles on hepatitis C drug sales Thursday, 30 Apr 2015 | 6:02 PM ET
    An associate scientist at Gilead Sciences.

    Sales of the novel hepatitis C drugs Sovaldi and Harvoni helped the company top Wall Street estimates.

  • WASHINGTON— The most-used medicines in Medicare's prescription drug program are generics, but the program spends the most on brand-name drugs, led by the heartburn treatment Nexium, according to an unprecedented release of government data on Thursday. Of more than 3,000 drugs prescribed that year, AstraZeneca's Nexium alone accounted for $2.5 billion of...

  • Is the market leadership changing?   Thursday, 30 Apr 2015 | 5:00 PM ET
    Is the market leadership changing?

    Are transport stocks and biotechs giving up their market leadership? Andrew Burkly of Oppenheimer and Rich Ross of Evercore ISI discuss with Brian Sullivan.

  • In a letter to Oklahoma Attorney General Scott Pruitt, drug manufacturer Akorn also said it was taking steps to ensure that the sedative midazolam is no longer made available to states for use in executions. "If your prisons have purchased Akorn products directly or indirectly for use in capital punishment we ask that you immediately return our products for a...

  • April 30- Pharmacy service provider Omnicare Inc is getting buyout interest from potential buyers, including Express Scripts Holding Co and CVS Health Corp, Bloomberg reported, citing people with knowledge of the matter. Omnicare is working with Bank of America Corp and Centerview Partners to explore options including a sale, the report said.

  • Since the review of healthcare antiseptics in the 1970' s, things have changed, the FDA noted, alluding to a shift in frequency of use, a hospital's infection control practices, technology and safety standards. The regulator is looking to play catch up with the scientific community after an independent panel of experts to the FDA raised similar concerns last year.

  • Pharma: No standout performers   Thursday, 30 Apr 2015 | 11:50 AM ET
    Pharma: No standout performers

    The earnings season for pharmaceutical has gone well so far, with the markets being happy with European pharma results, says Suki Virji, news editor at Scrip Intelligence.

  • FDA seeks more data on antiseptic ingredients Thursday, 30 Apr 2015 | 10:49 AM ET

    Alcohol and iodines are the most common active ingredients in such antiseptics, the FDA said, adding that home-use antiseptics such as antibacterial soap and hand sanitizers are not part of this evaluation. Accordingly, the FDA is requesting more data on absorption, potential hormonal effects and bacterial resistance of antiseptics under the...

  • NEW YORK/ LONDON, April 30- Pfizer Inc is the mystery bidder for Swedish Orphan Biovitrum AB, the rare disease specialist which disclosed this week that a potential buyer had made a preliminary offer, people with knowledge of the situation said. Sobi did not identify its potential acquirer when it revealed on Monday that it had received an approach, but Biogen and...

  • Cost in health profile in US is not sustainable: Cigna CEO

    David Cordani, Cigna CEO, discusses Cigna's business strategy, the high price of drugs, and Obamacare.

  • *Q1 adjusted EPS $1.36 vs $1.25 forecast. *Raises 2015 adjusted EPS forecast to $5.05- $5.35. TEL AVIV, April 30- Teva Pharmaceutical Industries, which is seeking to acquire rival Mylan Inc for over $40 billion, raised its full-year earnings outlook after posting a bigger-than-expected increase in first-quarter profit.

  • The Paris- based company said Thursday its net income was 1.05 billion euros, down from 1.12 billion in the first quarter of 2014. Sales were 8.8 billion euros, up 12 percent from last year. Sanofi expects slight growth this year under new CEO Olivier Brandicourt. Sanofi shares were down slightly Thursday morning, to 90.49 euros.

  • We've successfully hedged currencies: Novo Nordisk CFO

    Novo Nordisk CFO, Jesper Brandgaard, says the drug company has successfully hedged against currency effects and discusses plans for the weight loss product Saxenda

  • NEW YORK— Generic drugmaker Mylan raised its offer for over-the-counter medicines maker Perrigo Wednesday, but the Irish company again rejected Mylan's overture. Mylan said Wednesday it will pay $232.23 for each share of Perrigo in a mix of cash and stock, valuing Perrigo at about $34.1 billion. Perrigo, which is based in Dublin with U.S. headquarters in Allegan,...

  • April 29- Drugmaker Valeant Pharmaceuticals International Inc raised its earnings and sales forecasts for the year on Wednesday and said its chief financial officer will step down. Valeant shares rose in early trade in Toronto and New York. Valeant said Howard Schiller, the company's chief financial officer since December 2011, will step down once a...